Budesonide for prevention of irinotecan (CPT-11)-induced diarrhea. Results of a double-blind, placebo-controlled, multicenter, randomized phase-III-study in patients with advanced colorectal cancer (CRC).

30. Mai 2003

Karthaus, M., Ballo, H., Steinmetz, T., Geer, T., Schimke, J., Braumann, D., Behrens, R., Kindler, M., Greinwald, R., Kleeberg, U., 2003.